Enrolment initiated in World's First RCT with Sirolimus Coated Balloon for the treatment of Below-the-Knee (BTK) Peripheral Artery Disease
SINGAPORE, Aug. 27, 2020 -- (Healthcare Sales & Marketing Network) -- Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the FUTURE BTK trial (Randomized Controlled Trial of Fi... Devices, Interventional Concept Medical, critical limb ischemia, angioplasty, MagicTouch PTA, sirolimus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 27, 2020 Category: Pharmaceuticals Source Type: news

FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
Based on new data from two large clinical trials, FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk. Patients taking canagliflozin should notify your health care professionals right away if you develop new pain or tenderness, sores or ulcers, or infections in your legs or feet. Talk to your healthcare professional if you have questions or concerns. Do not stop taking your diabete...
Source: FDA Center for Drug Evaluation and Research - What's New - August 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Depression May Hinder Recovery From Narrowed Arteries
MONDAY, Aug. 17, 2020 -- People with peripheral artery disease (PAD) and depression have worse recovery than those who aren't depressed, a new study finds. That's especially true for women, the researchers said. " This is the first study to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 17, 2020 Category: General Medicine Source Type: news

Women Have More Depression With Peripheral Artery Disease
Depressive symptoms associated with worse disease - specific health status (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - August 13, 2020 Category: Psychiatry Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Psychiatry, Surgery, Anesthesiology & amp; Pain, Journal, Source Type: news

Women Have More Depression With Peripheral Artery Disease
THURSDAY, Aug. 13, 2020 -- Women with peripheral artery disease (PAD) have a higher burden of depressive symptoms compared with men, according to a study published online Aug. 12 in the Journal of the American Hospital Association. Qurat-ul-ain... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2020 Category: Pharmaceuticals Source Type: news

University of Edinburgh seeks - Research Fellow
The Usher Institute at the University of Edinburgh is seeking a highly skilled and motivated epidemiologist/research fellow to work in the field of vascular disease, including both the diagnosis and treatment of peripheral vascular diseases and the development of vascular complications of type 2 diabetes. The primary role will be to undertake a series of high quality systematic reviews on the prevention, diagnosis and treatment of vascular diseases, including abdominal aortic aneurysm, venous thromboembolism and peripheral arterial disease, within the core programme of work which constitutes the CSO funded research project...
Source: Cochrane News and Events - July 22, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

The Prevention of Cardiovascular Disease in Older Adults The Prevention of Cardiovascular Disease in Older Adults
This review summarizes evidence regarding the prevention of three common CVDs in older adults, with a focus on those over 75: stroke, coronary artery disease, and peripheral artery disease.Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Statin, Aspirin Uptake Low With Peripheral Artery Disease, Stroke
MONDAY, May 18, 2020 -- Uptake of guideline-directed preventive therapies is lower for patients with stroke and peripheral artery disease (PAD) compared with those with coronary artery disease (CAD), according to a study presented at the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2020 Category: Pharmaceuticals Source Type: news

Researchers suggest hot water therapy could be as effective as exercise for people with peripheral artery disease
(Natural News) Hot water therapy can improve functional ability and cardiovascular health in individuals with peripheral artery disease (PAD), according to a recent study published in the American Journal of Physiology-Heart and Circulatory Physiology. A team of researchers from New Zealand found evidence indicating that heat therapy via hot-water immersion yields the same health benefits as... (Source: NaturalNews.com)
Source: NaturalNews.com - May 13, 2020 Category: Consumer Health News Source Type: news

Micro Medical Solutions: First Case Completed in STAND Study, the Pivotal Clinical Trial of MicroStent
Major milestone reached in journey toward FDA approval for potentially limb-saving treatment of peripheral artery disease WILMINGTON, Mass., May 12, 2020 -- (Healthcare Sales & Marketing Network) -- Micro Medical Solutions (MMS) today announced the fir... Devices, Interventional Micro Medical Solutions, MicroStent, vascular stent, limb salvage (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 12, 2020 Category: Pharmaceuticals Source Type: news

Heavy Drinking Tied to Raised Stroke Risk, Study Finds
TUESDAY, May 5, 2020 -- Lots of boozing might increase your risk for a stroke, Swedish researchers report. Heavy alcohol use can triple your risk for peripheral artery disease, a narrowing of arteries that results in reduced blood flow, usually to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 5, 2020 Category: General Medicine Source Type: news

High Alcohol Consumption May Be Causally Tied to Stroke, PAD
TUESDAY, May 5, 2020 -- Higher alcohol consumption may be causally associated with an increased risk for stroke and peripheral artery disease, according to a study published online May 5 in Circulation: Genomic and Precision Medicine. Susanna C.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2020 Category: Pharmaceuticals Source Type: news

Genetic study ties higher alcohol consumption to increased stroke and PAD risk
(American Heart Association) Using genetic analysis, researchers found higher alcohol consumption increased risks for stroke and peripheral artery disease (PAD).Studies using genetic analysis don't rely on observational data, which often use self-reported data and could be subject to unreported risk factors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news

Work Stress May Raise the Risk for Peripheral Artery Disease Work Stress May Raise the Risk for Peripheral Artery Disease
People with very demanding jobs but little control are more likely to be hospitalized with peripheral artery disease than those with less work-related stress, a new study finds.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 30, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Job Strain Linked to Increase in Risk for PAD Hospitalization
TUESDAY, April 28, 2020 -- Job strain is associated with a 1.41-fold increase in the average risk for peripheral artery disease (PAD) hospitalization, according to a study published online April 28 in the Journal of the American Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 28, 2020 Category: Pharmaceuticals Source Type: news

Job Strain May Boost Odds of Serious Artery Disease
TUESDAY, April 28, 2020 -- Work stress may increase your risk for ending up in the hospital with peripheral artery disease, a new study suggests. Peripheral artery disease (PAD) occurs when cholesterol or other fatty substances accumulate in blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 28, 2020 Category: General Medicine Source Type: news

On-the-job stress raises risk for peripheral artery disease, study finds
Stress on the job may increase a person's risk for peripheral artery disease, according a study published Tuesday in the Journal of the American Heart Association. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 28, 2020 Category: Consumer Health News Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” sai...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

COVID-19 Business Updates Provide Some Clarity
The unknowns still outnumber the knowns, but recent business updates provide some clarity around how the medical device industry is fairing during the COVID-19 pandemic. First and foremost, it is clear that companies are hurting in the areas of elective procedures, which are being deferred. But there may be some silver linings hidden amongst the bad news. Needham & Co. medtech analyst Mike Matson estimates that medical device sales across the industry will continue to drop by an average of 40% to 50% until the economy begins to reopen and hospitals start to resume elective procedures. Matson's e...
Source: MDDI - April 10, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: COVID-19 Business Source Type: news

Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
(American College of Cardiology) The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

Larger Absolute Rivaroxaban Benefit in Diabetes: COMPASS Larger Absolute Rivaroxaban Benefit in Diabetes: COMPASS
The new vascular low dose of rivaroxaban has gotten off to a slow start, but these new subgroup results may stimulate use in patients with diabetes and stable coronary or peripheral artery disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefi...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

28.03.20: Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology
Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularizationThe only clinical outcome study to demonstrate the benefits of a combined antithrombotic and anti-platelet therapy in these vulnerable patients who currently have limited treatment options / Risk of acute limb ischemia was significantly reduced by 33% in these patients compared to those receiving aspirin alone / There was no significant increase in TIMI major bleeding, the principal safety outcome of the trialmehr ... (Source...
Source: Bayer IR Newsfeed: Events - March 28, 2020 Category: Pharmaceuticals Source Type: news

Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto ™ ) Phase III studies (for specialized target groups only)
The VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate Bayer’s ongoing commitment to the treatment of cardiovascular disease (Source: Bayer Company News)
Source: Bayer Company News - March 20, 2020 Category: Pharmaceuticals Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

20.03.20: Not intended for U.S. and UK Media - American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual):
Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto™) Phase III studiesThe VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate...
Source: Bayer IR Newsfeed: Events - March 20, 2020 Category: Pharmaceuticals Source Type: news

Study maps landmarks of peripheral artery disease to guide treatment development
(University of Illinois at Urbana-Champaign, News Bureau) Novel biomedical advances that show promise in the lab often fall short in clinical trials. For researchers studying peripheral artery disease, this is made more difficult by a lack of standardized metrics for what recovery looks like. A new study from University of Illinois at Urbana-Champaign researchers identifies major landmarks of PAD recovery, creating signposts for researchers seeking to understand the disease and develop treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 2, 2020 Category: International Medicine & Public Health Source Type: news

Cocoa a Novel Rx for Peripheral Artery Disease? Cocoa a Novel Rx for Peripheral Artery Disease?
Results of a pilot randomized trial suggest a beverage with>85% cacao may also improve symptoms of PAD, including 6-minute walk and perfusion in the legs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 26, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Cocoa Consumption May Improve Walking Performance in PAD
FRIDAY, Feb. 14, 2020 -- Cocoa consumption may improve walking performance in individuals with peripheral artery disease (PAD), according to a study published online Feb. 14 in Circulation Research. Mary M. McDermott, M.D., from the Northwestern... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2020 Category: Pharmaceuticals Source Type: news

Hot Chocolate Could Help Ease Painful Clogged Leg Vessels
FRIDAY, Feb. 14, 2020 -- Could hot chocolate deliver relief to those suffering from the painful condition known as peripheral artery disease (PAD)? A small, new study says it's entirely possible. Though you may be picturing a steaming cup of hot... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 14, 2020 Category: General Medicine Source Type: news

Cocoa may improve lower-leg blood flow, walking in peripheral artery disease
Cocoa may help improve walking and lower-leg blood flow in adults with peripheral artery disease, according to a study published Friday in the journal Circulation Research. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 14, 2020 Category: Consumer Health News Source Type: news

Cocoa may improve leg blood flow, walking in peripheral artery disease
Cocoa may help improve walking and lower-leg blood flow in adults with peripheral artery disease, according to a study published Friday in the journal Circulation Research. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 14, 2020 Category: Consumer Health News Source Type: news

PAD Patients Often Don't Receive Evidence-Based Care From Specialty Clinics PAD Patients Often Don't Receive Evidence-Based Care From Specialty Clinics
Patients with peripheral artery disease (PAD) attending specialty clinics do not always receive evidence-based care, and supervised exercise therapy (SET), in particular, is often missed, an international registry study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Medtech in a Minute: SFA Competition, Check-Cap Inches Toward US Market, and More
Gore Has a New Challenger in SFA PQ Bypass is set to become the first company since 2004 to have an IDE trial for a stent to treat peripheral artery disease in the superficial femoral artery (SFA). If all goes as planned for the company, its Torus Stent Graft will compete head-to-head with W.L. Gore's Viabahn system. PQ Bypass could potentially file for FDA approval in 2021.   Should This Blood Test Be Part of the Standard Pre-Op for Most Surgeries? A common cardiac blood test done before surgery can predict who will experience adverse outcomes after most types of surgery, said researchers from Hami...
Source: MDDI - January 4, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

20 Private Companies to Watch in 2020
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - December 24, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

20 Private Medtech Companies to Watch in 2020
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - December 24, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

PQ Bypass Steps into SFA Arena to Compete Against Gore
It might be cliché to say here comes a new challenger – but in the case of PQ Bypass it’s quite true. The Milpitas, CA-based firm said it will be the first company since 2004 to have an IDE trial for a stent to treat peripheral artery disease in the superficial femoral artery (SFA). The other company to have an SFA IDE trial is W.L. Gore. The Newark, DE-based company would eventually win a nod from FDA for the Viabahn system. PQ Bypass made a major advancement in its bid to get the Torus Stent Graft on the market last week as the company reported it received approval for cov...
Source: MDDI - December 23, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

5 More Private Medtech Companies to Keep Tabs On
MedTech analysts continue to keep a watchful eye on the private sector. Needham & Co.'s Mike Matson recently called attention to five private medical device companies he finds interesting, adding to three previous lists the analyst published earlier this year. Matson was not the only medtech analyst keeping tabs on up and coming private companies in 2019. In January, Canaccord Genuity's Jason Mills highlighted 16 potentially disruptive medtech companies in the private sector. Here are the five companies Matson most recently highlighted. 7D Surgical...
Source: MDDI - December 16, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Leg Pain Could Spell Peripheral Artery Disease for Some
FRIDAY, Nov. 29, 2019 -- Leg pain while walking or doing other activities could be a sign of peripheral artery disease, an expert says. Peripheral artery disease (PAD) develops silently, narrowing blood vessels until a shortfall in the supply of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 29, 2019 Category: General Medicine Source Type: news

Not getting enough magnesium? You might be at risk of heart disease, depression
(Natural News) Being deficient in nutrients comes with serious health risks. Having low levels of magnesium, for instance, can increase your risk of cardiovascular diseases and depression. In a study published in the journal Atherosclerosis, researchers found that people with low magnesium levels are at risk of developing peripheral artery disease (PAD). When the participants... (Source: NaturalNews.com)
Source: NaturalNews.com - November 27, 2019 Category: Consumer Health News Source Type: news

Medtronic FDA Approval Marks a Turnaround in the Paclitaxel Story
Paclitaxel-coated balloons and paclitaxel-eluting stents caused quite the stir for manufacturers and physicians this year, but an FDA approval this week marks a major step forward for this category of devices. The agency approved Medtronic's IN.PACT AV drug-coated balloon for the treatment of failing arteriovenous access in patients with end-stage renal disease (ESRD) undergoing dialysis. AV fistulae are created and used to enable hemodialysis for patients with ESRD. Over time, vessel restenosis limits the ability to use AV fistulae effectively. In order to restore function, patients often undergo one to three ...
Source: MDDI - November 22, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Einstein Awarded $8 Million to Use Wearable Tech to Improve Detection of Leg Arterial Disease
November 21, 2019—(BRONX, NY)—Lower extremity arterial disease (LEAD) is a debilitating but under-recognized condition usually caused by fatty plaque buildup in arteries carrying blood from the heart to the legs. More commonly known as peripheral artery disease, this increasingly common condition affects more than 8 million Americans, including up to 20% of those over the age of 60, and over 200 million people worldwide. Left untreated, LEAD can result in disability, amputations, and death. (Source: Einstein News)
Source: Einstein News - November 21, 2019 Category: Universities & Medical Training Source Type: news

LimFlow Shows ‘PROMISE’ During VIVA
A firm that was labeled one of Medtech’s 16 Most Promising Private Companies by Canaccord Genuity earlier this year, has strong results from a study that will help with FDA approval. LimFlow recently announced positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the Percutaneous Deep Vein Arterialization (pDVA) System. The Paris-based company presented the data during the Vascular Interventional Advances [VIVA] Conference held in Las Vegas, earlier this month. The company’s technology is used for the treatment of chronic limb-threatening ischem...
Source: MDDI - November 18, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

Boston Scientific Touts Positive Data on Two Paclitaxel Devices
Boston Scientific announced positive data Tuesday for two paclitaxel devices during separate late-breaking clinical trial presentations at the annual Vascular InterVentional Advances (VIVA) meeting in Las Vegas. Paclitaxel-coated balloons and paclitaxel-eluting stents caused quite the stir for the drug-coated balloon manufacturers and physicians this year, but presentations like these could go a long way toward helping the market rebound. To recap, paclitaxel balloons and stents received some bad press in late December 2018 after a meta-analysis showed...
Source: MDDI - November 5, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

FDA Okays Two Stellarex DCBs for Peripheral Artery Disease FDA Okays Two Stellarex DCBs for Peripheral Artery Disease
The paclitaxel-coated balloon is now available in seen lengths to treat patients with femoropopliteal disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 15, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Sky Medical Technology Nabs FDA Clearance for VTE Device
Sky Medical Technology Ltd. won FDA clearance for a device that stimulates calf muscles to prevent venous thrombosis in non-surgical patients at risk for venous thromboembolism. The Daresbury, England-based company said the geko device is the first muscle pump activator of its kind to be cleared by FDA for VTE prevention across all patients. Sky Medical Technology’s geko is a non-invasive battery-powered, wearable therapy device that is about the size of wristwatch. The technology is worn at the knee. Geko works by gently stimulating the common peroneal nerve, activating the calf and foot muscle pumps, re...
Source: MDDI - October 12, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

AngioDynamics Has Laser Focus on PAD with New Acquisition
The M&A’s just keep coming this week as AngioDynamics announced a plan acquire Eximo Medical. Latham, NY-based AngioDynamics will pick up the company for about $46 million in up-front consideration with the possibility of up to $20 million in milestones. The announcement comes a day after Lantheus Holdings revealed its intention to acquire Progenics Pharmaceuticals. Eximo has developed technology that delivers short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures. The technology addresses the risk of perfo...
Source: MDDI - October 3, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Blood Flow Monitoring Device - FlowMet-R Gets FDA 510K Clearance
Laser Associated Sciences' Non-Invasive Device Disrupting the Industry IRVINE, Calif., Oct. 2, 2019 -- (Healthcare Sales & Marketing Network) -- Laser Associated Sciences (LAS), a medical device company based in Irvine, California, announced that its b... Devices, Monitoring, FDA Laser Associated Sciences, FlowMet-R, Blood Flow, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 2, 2019 Category: Pharmaceuticals Source Type: news

Understanding the trends in lower-extremity amputations for diabetes and peripheral artery disease
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - September 20, 2019 Category: Hospital Management Tags: Hospital News Source Type: news